Fructose and the Metabolic Syndrome: Pathophysiology and Molecular Mechanisms

Nutrition Reviews

Volumn 65, Issue SUPPL.1, 2007, Pages

  Rutledge, Angela C ^a   Adeli, Khosrow ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Fructose; Hepatic lipogenesis; Insulin resistance; JNK; Metabolic syndrome; NFkB; Obesity; TNF

Indexed keywords

FRUCTOSE; SWEETENING AGENT;

ANIMAL; DISEASE MODEL; DRUG EFFECT; HUMAN; METABOLIC SYNDROME X; METABOLISM; OBESITY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; FRUCTOSE; HUMANS; METABOLIC SYNDROME X; OBESITY; SIGNAL TRANSDUCTION; SWEETENING AGENTS;

EID: 34547479904     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2007.tb00322.x     Document Type: Article

References (72)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 suppl 5):S1-S85.
2. Havel PJ. Dietary fructose: implications for dysregu-lation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005;63:S133-S157.
3. Ludwig DS, Gortmaker SL Programming obesity in childhood. Lancet 2004;364:S226-S227.
4. Jurgens H., Haass W., Castaneda TR, et al. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res 2005;13:S1146-S1156.
5. Basciano H., Federico L., Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005;2:S5.
6. Nagata R., Nishio Y., Sekine O., et al. Single nucleo-tide polymorphism (-468 Gly to A) at the promoter region of SREBP-1c associates with genetic defect of fructose-induced hepatic lipogenesis [corrected]. J Biol Chem 2004;279:S29031-S29042.
7. Le KA, Tappy L. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 2006;9:S469-S475.
8. Hansen E., Hajri T., Abumrad NN. Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus. Surgery 2006;139:S711-S716.
9. Reynisdottir S., Dauzats M., Thorne A., Langin D. Comparison of hormone-sensitive lipase activity in visceral and subcutaneous human adipose tissue. J Clin Endocrinol Metab 1997;82:S4162-S4166.
10. Kahn BB. Alterations in glucose transporter expression and function in diabetes: mechanisms for insulin resistance. J Cell Biochem 1992;48:S122-S128.
11. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6:depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:S847-S850.
12. Hotamisligil GS, Peraldi P., Budavari A., Ellis R., White MF, Spiegelman BM. IRS-1 -mediated inhibition of insulin receptor tyrosine kinase activity in TNF-al-pha- and obesity-induced insulin resistance. Science 1996;271:S665-S668.
13. Weickert MO, Pfeiffer AF. Signalling mechanisms linking hepatic glucose and lipid metabolism. Dia-betologia 2006;49:S1732-S1741.
14. Kerouz NJ, Horsch D., Pons S., Kahn CR. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 1997;100:S3164-S3172.
15. Shimomura I., Matsuda M., Hammer RE, Bashmakov Y., Brown MS, Goldstein JL Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice Mol Cell 2000;6:S77-S86.
16. Taghibiglou C., Rashid-Kolvear F., Van Iderstine SC, et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of pro-tein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 2002;277:S793-S803.
17. Wei Y., Pagliassotti MJ. Hepatospecific effects of fructose on c-jun NH2-terminal kinase: implications for hepatic insulin resistance. Am J Physiol Endocrinol Metab 2004;287:SE926-SE933.
18. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem 1999;274:S1865-S1868.
19. Wolfrum C., Asilmaz E., Luca E., Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogen-esis in the liver during fasting and in diabetes. Nature 2004;432:S1027-S1032.
20. Wolfrum C., Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 2006;3:S99-S110.
21. Goodyear LJ, Giorgino F., Sherman LA, Carey J., Smith RJ, Dohm GL Insulin receptor phosphoryla-tion, insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects J Clin Invest 1995;95:S2195-S2204.
22. Goldstein BJ. Protein-tyrosine phosphatases and the regulation of insulin action. J Cell Biochem 1992;48:S33-S42.
23. Qiu W., Avramoglu RK, Dube N., et al. Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1 B overexpression, knockout, and RNAi studies. Diabetes 2004;53:S3057-S3066.
24. Klaman LD, Boss O., Peroni OD, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1 B-deficient mice. Mol Cell Biol 2000;20:S5479-S5489.
25. Virkamaki A., Ueki K., Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999;103:S931-S943.
26. Sasaoka T., Wada T., Tsuneki H. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol Ther 2006;112:S799-S809.
27. Stiles B., Wang Y., Stahl A., et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 2004;101:S2082-S2087.
28. Clement S., Krause U., Desmedt F., et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001;409:S92-S97.
29. Fukui K., Wada T., Kagawa S., et al. Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5'-phosphatase 2) on insulin signaling and glucose metabolism in mice. Diabetes 2005;54:S1958-S1967.
30. Carlson CJ, Koterski S., Sciotti RJ, Poccard GB, Rondinone CM. Enhanced basal activation of mito-gen-activated protein kinases in adipocytes from type 2 diabetes: potential role of p38 in the down-regulation of GLUT4 expression. Diabetes 2003;52:S634-S641.
31. Tsai J., Qiu W., Kohen-Avramoglu R., Adeli K. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells. Potential role of ERK in VLDL-ApoB100 particle assembly. Arterioscler Thromb Vasc Biol 2007;27:S211-S218.
32. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 2005;54:S1676-S1683.
33. Corbould A., Zhao H., Mirzoeva S., Aird F., Dunaif A. Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 2006;55:S751-S759.
34. Hirosumi J., Tuncman G., Chang L., et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:S333-S336.
35. Lazar MA. The humoral side of insulin resistance. Nat Med 2006;12:S43-S44.
36. Li Z., Diehl AM. Innate immunity in the liver. Curr Opin Gastroenterol 2003;19:S565-S571.
37. Weisberg SP, McCann D., Desai M., Rosenbaum M., Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:S1796-S1808.
38. Choi S., Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005;21:S702-S707.
39. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:S239-S252.
40. Bandyopadhyay GK, Yu JG, Ofrecio J., Olefsky JM. Increased expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 2005;54:S2351-S2359.
41. Nakatani Y., Kaneto H., Kawamori D., et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004;279:S45803-S45809.
42. Kelley GL, Allan G., Azhar S. High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology 2004;145:S548-S555.
43. Wei Y., Wang D., Pagliassotti MJ. Fructose selectively modulates c-jun N-terminal kinase activity and insulin signaling in rat primary hepatocytes. J Nutr 2005;135:S1642-S1646.
44. Taghibiglou C., Carpentier A., Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellu-lar ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000;275:S8416-S8425.
45. Kim HJ, Hawke N., Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13:S738-S747.
46. Cai D., Yuan M., Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:S183-S190.
47. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005;11:S191-S198.
48. Boden G., She P., Mozzoli M., et al. Free fatty acids produce insulin resistance and activate the proin-flammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005;54:S3458-S3465.
49. Janabi M., Yamashita S., Hirano K., et al. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 2000;20:S1953-S1960.
50. Yuan M., Konstantopoulos N., Lee J., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293(5535):S1673-S1677.
51. Rohl M., Pasparakis M., Baudler S., et al. Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest 2004;113:S474-S481.
52. Chung S., Brown JM, Provo JN, Hopkins R., McIn-tosh MK. Conjugated linoleic acid promotes human adipocyte insulin resistance through NFkappaB-de-pendent cytokine production. J Biol Chem 2005;280:S38445-S38456.
53. Gao Z., Zuberi A., Quon MJ, Dong Z., Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 2003;278:S24944-S24950.
54. Dietze D., Ramrath S., Ritzeler O., Tennagels N., Hauner H., Eckel J. Inhibitor kappaB kinase is involved in the paracrine crosstalk between human fat and muscle cells. Int J Obes Relat Metab Disord 2004;28:S985-S992.
55. Sell H., Eckel J., Dietze-Schroeder D. Pathways leading to muscle insulin resistance. The muscle-fat connection. Arch Physiol Biochem 2006;112:S105-S113.
56. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006;68:S159-S191.
57. Tobin KA, Ulven SM, Schuster GU, et al. Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J Biol Chem 2002;277:S10691-S10697.
58. Cagen LM, Deng X., Wilcox HG, Park EA, Raghow R., Elam MB. Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements. Biochem J 2005;385:S207-S216.
59. Sinal CJ, Tohkin M., Miyata M., Ward JM, Lambert G., Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid ho-meostasis. Cell 2000;102:S731-S744.
60. Zhang Y., Lee FY, Barrera G., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006;103:S1006-S1011.
61. Cariou B., Staels B. The expanding role of the bile acid receptor FXR in the small intestine. J Hepatol 2006;44:S1213-S1215.
62. Watanabe M., Houten SM, Wang L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:S1408-S1418.
63. Hirokane H., Nakahara M., Tachibana S., Shimizu M., Sato R. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 2004;279:S45685-S45692.
64. Bilz S., Samuel V., Morino K., Savage D., Choi CS, Shulman GI. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipid-emic hamsters. Am J Physiol Endocrinol Metab 2006;290:SE716-SE722.
65. Yamashita H., Takenoshita M., Sakurai M., et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci USA 2001;98:S9116-S9121.
66. Dentin R., Denechaud PD, Benhamed F., Girard J., Postic C. Hepatic gene regulation by glucose and polyunsaturated fatty acids: a role for ChREBP. J Nutr 2006;136:S1145-S1149.
67. Federico LM, Naples M., Taylor D., Adeli K. Intestinal insulin resistance and aberrant production of apoli-poprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phospha-tase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 2006;55:S1316-S1326.
68. Dentin R., Girard J., Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c):two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005;87:S81-S86.
69. Zoltowska M., Ziv E., Delvin E., et al. Circulating lipoproteins and hepatic sterol metabolism in Psam-momys obesus prone to obesity, hyperglycemia and hyperinsulinemia. Atherosclerosis 2001;157:S85-S96.
70. Sullivan MP, Cerda JJ, Robbins FL, Burgin CW, Beatty RJ. The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab Anim Sci 1993;43:S575-S578.
71. Nistor A., Bulla A., Filip DA, Radu A. The hyperlipid-emic hamster as a model of experimental atherosclerosis. Atherosclerosis 1987;68:S159-S173.
72. Carpentier A., Taghibiglou C., Leung N., et al. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 2002;277:S28795-S28802.